Opiant Pharmaceuticals (Opiant Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals Total Inventories?

Opiant Pharmaceuticals's total inventories for the quarter that ended in Sep. 2022 was $0.00 Mil. Opiant Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2022 to the quarter that ended in Sep. 2022 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Opiant Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was $2.70.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Opiant Pharmaceuticals Total Inventories Historical Data

The historical data trend for Opiant Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Total Inventories Chart

Opiant Pharmaceuticals Annual Data

Trend

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Dec18

Dec19

Dec20

Dec21

Total Inventories

Get a 7-Day Free Trial

Opiant Pharmaceuticals Quarterly Data
	Oct17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Opiant Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Opiant Pharmaceuticals (NAS:OPNT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Opiant Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is

	Net-Net Working Capital Per Share (Q: Sep. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(35.376	+	0.75 * 0.041	+	0.5 * 0	-	21.448
-	0	-	0)	/	5.16495
=	2.70

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Opiant Pharmaceuticals's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2022 )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Opiant Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2022 )	/	Average Total Inventories (Q: Sep. 2022 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Opiant Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Opiant Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401

Website

https://www.opiant.com

Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Executives

David D O'toole	officer: Chief Financial Officer	1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath	other: UK Managing Director	C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal	director, 10 percent owner, officer: Chief Executive Officer	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick	officer: Chief Scientific Officer	C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman	other: General Counsel	233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth	officer: Chief Commercial Officer	233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair	director, 10 percent owner, officer: Executive Chairman	86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson	other: General Counsel	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134